NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Roche Holding AG (SW: RO)

 
RO Technical Analysis
5
As on 6th Feb 2025 RO STOCK Price closed @ 306.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 259.38 & Strong Buy for SHORT-TERM with Stoploss of 268.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ROSTOCK Price

Open 311.40 Change Price %
High 311.40 1 Day -5.40 -1.73
Low 305.60 1 Week 6.20 2.07
Close 306.20 1 Month 35.40 13.07
Volume 24240 1 Year 34.40 12.66
52 Week High 312.00 | 52 Week Low 231.60
 
SW Switzerland Most Active Stocks
CSGN 0.82 0.00%
CSGN 0.82 0.00%
UBSG 30.16 3.64%
UBSG 30.16 3.64%
NOVN 97.71 -0.59%
NOVN 97.71 -0.59%
NESN 77.50 0.31%
NESN 77.50 0.31%
PRFN 0.03 50.00%
ABBN 49.60 1.16%
 
SW Switzerland Top Gainers Stocks
PRFN 0.03 50.00%
PRFN 0.03 50.00%
CADN 0.03 50.00%
BLS 0.13 18.18%
BLS 0.13 18.18%
BLS 0.13 18.18%
NEWN 0.94 17.50%
EVE 1.38 11.29%
EVE 1.38 11.29%
EVE 1.38 11.29%
 
SW Switzerland Top Losers Stocks
STLN 1.50 -13.79%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
LEON 17.70 -11.06%
 
 
RO
Daily Charts
RO
Intraday Charts
Whats New @
Bazaartrend
RO
Free Analysis
 
RO Important Levels Intraday
RESISTANCE317.38
RESISTANCE313.79
RESISTANCE311.58
RESISTANCE309.36
SUPPORT303.04
SUPPORT300.82
SUPPORT298.61
SUPPORT295.02
 
RO Forecast February 2025
4th UP Forecast350.52
3rd UP Forecast336.31
2nd UP Forecast327.52
1st UP Forecast318.74
1st DOWN Forecast293.67
2nd DOWN Forecast284.88
3rd DOWN Forecast276.09
4th DOWN Forecast261.88
 
RO Weekly Forecast
4th UP Forecast325.47
3rd UP Forecast319.29
2nd UP Forecast315.47
1st UP Forecast311.65
1st DOWN Forecast300.75
2nd DOWN Forecast296.93
3rd DOWN Forecast293.11
4th DOWN Forecast286.93
 
RO Forecast2025
4th UP Forecast465.37
3rd UP Forecast414.32
2nd UP Forecast382.77
1st UP Forecast351.22
1st DOWN Forecast261.18
2nd DOWN Forecast229.63
3rd DOWN Forecast198.08
4th DOWN Forecast147.03
 
 
RO Other Details
Segment EQ
Market Capital 309489172480.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
RO Address
RO
 
RO Latest News
 
Your Comments and Response on Roche Holding AG
 
RO Business Profile
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick's samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. Address: Konzern Hauptsitz, Basel, Switzerland, 4070
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service